Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On Mary 14, 2026, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026.</li><li>The company continues preparations for an upcoming Phase 2 clinical trial of EB06 (anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo.</li><li>Edesa has selected the clinical research company and outreach to potential clinical sites and investigators has begun.</li></ul>

On Mary 14, 2026, Edesa Biotech, Inc. (EDSA) announced financial results for the second quarter of fiscal year 2026 that ended March 31, 2026.The company continues preparations for an upcoming Phase 2 clinical trial of EB06 (anti-CXCL10 monoclonal antibody) in patients with moderate-to-severe nonsegmental vitiligo.Edesa has selected the clinical research company and outreach to potential clinical sites and investigators has begun.

EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial